ADC advances at AACR: target diversity, optimizing internalization

Expanding the targets of antibody-drug conjugates, and making the therapies more effective even when target expression is low, are among the top research priorities for the modality, based on the large crop of ADC abstracts at AACR 2023.

BioCentury’s analysis of the 6,039 abstracts presented at the American Association for Cancer Research conference this week identified 143 covering antibody-drug conjugates (ADCs) against an impressive 46 different targets...